Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856487 | 0.97 | EPHX1 (0.52) | EPHX1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL13668221 | 0.97 | EPHX1 (0.52) | EPHX1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL17974512 | 0.97 | EPHX1 (0.52) | EPHX1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL2599824 | 0.92 | EPHX1 (0.59) | EPHX1TSHRALDH1A1HTR1BMAPT | |
| SCHEMBL23342876 | 0.90 | EPHX1 (0.64) | EPHX1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL14051928 | 0.90 | EPHX1 (0.64) | EPHX1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL13997666 | 0.90 | EPHX1 (0.56) | EPHX1TSHRCYP3A4ALDH1A1HTR1B | |
| SCHEMBL8979942 | 0.90 | EPHX1 (0.64) | EPHX1TSHRALDH1A1HTR1BMAPT | |
| SCHEMBL15511002 | 0.90 | EPHX1 (0.64) | EPHX1TSHRALDH1A1HTR1BMAPT | |
| SCHEMBL15510919 | 0.90 | EPHX1 (0.64) | EPHX1TSHRALDH1A1HTR1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395549-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | Oerth Bio LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023034411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| WO-2021148563-A1 | WATERBORNE CROSSLINKER COMPOSITION | COVESTRO (NETHERLANDS) B.V. (NL) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020233512-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | 成都海创药业有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| EP-2708529-B1 | METHOD FOR MANUFACTURING PARTICLES | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9796831-B2 | Process for producing particles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| CN-103974929-A | Method for producing hydrohalic acid salt of halogenated alkyl amine | SUMITOMO CHEMICAL CO | 2014-08-06 | — | — | CN | disclosed |
| EP-2708529-A1 | METHOD FOR MANUFACTURING PARTICLES | Sumitomo Chemical Company Limited (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20140065337-A1 | PROCESS FOR PRODUCING PARTICLES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| CN-103534236-A | Method for producing granules | SUMITOMO CHEMICAL CO | 2014-01-22 | — | — | CN | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009099582-A2 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | EPHX1 3192/4885TSHR 3418/4885CYP3A4 4863/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | EPHX1 2615/4885TSHR 4023/4885CYP3A4 4833/4885 |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | GPR119, IAPP, LIPA | EPHX1 3223/4885TSHR 550/4885CYP3A4 4454/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | EPHX1 3575/4885TSHR 2815/4885CYP3A4 453/4885 |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | IAPP, PNLIP, AMY2A | EPHX1 1435/4885TSHR 1497/4885CYP3A4 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.